Atlas Trials

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

Clinical trial NCT06730009 · RECRUITING

Trial details

NCT number
NCT06730009
Sponsor
Medigen Biotechnology Corporation
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pancreatic Carcinoma Stage IICholangiocarcinoma Resectable
Start date
2024-10-21
Primary completion
2029-01-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.